In Situ Genetic Correction of the Sickle Cell Anemia Mutation in Human Induced Pluripotent Stem Cells Using Engineered Zinc Finger Nucleases
Open Access
- 2 September 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in The International Journal of Cell Cloning
- Vol. 29 (11), 1717-1726
- https://doi.org/10.1002/stem.718
Abstract
The combination of induced pluripotent stem cell (iPSC) technology and targeted gene modification by homologous recombination (HR) represents a promising new approach to generate genetically corrected, patient-derived cells that could be used for autologous transplantation therapies. This strategy has several potential advantages over conventional gene therapy including eliminating the need for immunosuppression, avoiding the risk of insertional mutagenesis by therapeutic vectors, and maintaining expression of the corrected gene by endogenous control elements rather than a constitutive promoter. However, gene targeting in human pluripotent cells has remained challenging and inefficient. Recently, engineered zinc finger nucleases (ZFNs) have been shown to substantially increase HR frequencies in human iPSCs, raising the prospect of using this technology to correct disease causing mutations. Here, we describe the generation of iPSC lines from sickle cell anemia patients and in situ correction of the disease causing mutation using three ZFN pairs made by the publicly available oligomerized pool engineering method (OPEN). Gene-corrected cells retained full pluripotency and a normal karyotype following removal of reprogramming factor and drug-resistance genes. By testing various conditions, we also demonstrated that HR events in human iPSCs can occur as far as 82 bps from a ZFN-induced break. Our approach delineates a roadmap for using ZFNs made by an open-source method to achieve efficient, transgene-free correction of monogenic disease mutations in patient-derived iPSCs. Our results provide an important proof of principle that ZFNs can be used to produce gene-corrected human iPSCs that could be used for therapeutic applications.Funding Information
- NIH (R01 GM069906)
- Pioneer Award (DP1 OD006862)
- National Science Foundation Graduate Research fellowships
- Start-up funds of the Institute for Stem Cell Biology and Regenerative Medicine
- Stanford University School of Medicine and the Donald E. and Delia B. Baxter Foundation
- CIRM Training Grant for postdoctoral fellows
- New York Stem Cell Foundation Robertson Investigator
- Jim and Ann Orr Massachusetts General Hospital Research Scholar
This publication has 49 references indexed in Scilit:
- Engineering of Human Pluripotent Stem Cells by AAV-mediated Gene TargetingMolecular Therapy, 2010
- ZiFiT (Zinc Finger Targeter): an updated zinc finger engineering toolNucleic Acids Research, 2010
- Modeling Disease in Human ESCs Using an Efficient BAC-Based Homologous Recombination SystemCell Stem Cell, 2010
- Technical Challenges in Using Human Induced Pluripotent Stem Cells to Model DiseaseCell Stem Cell, 2009
- Gene targeting in human pluripotent stem cells with adeno-associated virus vectorsBiochemical and Biophysical Research Communications, 2009
- Oligomerized pool engineering (OPEN): an 'open-source' protocol for making customized zinc-finger arraysNature Protocols, 2009
- Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleasesNature Biotechnology, 2009
- Generation of Human Induced Pluripotent Stem Cells by Direct Delivery of Reprogramming ProteinsCell Stem Cell, 2009
- High-frequency modification of plant genes using engineered zinc-finger nucleasesNature, 2009
- Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genomeProceedings of the Japan Academy, Series B, 2009